• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Doug Kass
    • Bruce Kamich
    • Jim Cramer
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing

Arrowhead Pharmaceuticals Is Flying Higher on the Charts

Before I give my recommendation I want to visit with the charts and indicators.
By BRUCE KAMICH
Oct 18, 2019 | 03:10 PM EDT
Stocks quotes in this article: ARWR, JNJ, AMGN

For his "Executive Decision" segment of Mad Money Thursday night, Jim Cramer spoke with Christopher Anzalone, president and CEO of Arrowhead Pharmaceuticals (ARWR) , the development-stage biotech focusing on gene therapy. The company held an analyst day in New York City today.

Anzalone explained that Arrowhead is pioneering gene therapies developed around the concept of RNA interference, which acts to silence, or turn off, certain genes that are known to cause disease. The company originally focused on just the liver, but is now broadening its scope outside of the liver and is also developing technologies to silence multiple genes at the same time.

Arrowhead currently has big name partnerships with Johnson & Johnson (JNJ) and Amgen (AMGN) to help them develop and commercialize various drugs based off of the company's technology. Arrowhead recently announced a successful trial for cystic fibrosis, for example, that included 110 patients and had no serious adverse events.

Shares of Arrowhead are up 171% over the past year and Cramer continued his recommendation. 

In this daily bar chart of ARWR, below, we can see an impressive rally where this stock has tripled in just the past 12 months. Prices are above the rising 50-day simple moving average line and perhaps a bit extended above the rising 200-day line.

The daily On-Balance-Volume (OBV) line is nearly at a new high for the move up telling us that buyers of ARWR have been more aggressive and the movement of this indicator confirms the price gains.

The trend-following Moving Average Convergence Divergence (MACD) oscillator crossed above the zero line last week for a fresh outright go long signal.

In this weekly bar chart of ARWR, below, we can see that prices have made a tremendous rally over the past three years. (Wouldn't be nice to go back in time and go long in size in 2017?) Prices are above the rising 40-week moving average line.

The weekly OBV line has been in a bull move the past three years telling us that investors have accumulated this stock steadily. The MACD oscillator on this longer time frame is about to cross to the upside again for a fresh outright buy signal.

In this first Point and Figure chart of ARWR, below, we can see a $44 price projection. Bullish but we could reach that level in a few weeks the way this stock has been advancing.

In this second Point and Figure chart of ARWR, below, we filtered out some price action by looking at only closing prices. Here the upside price target is the $54 area.

Bottom line strategy: These four charts of ARWR tell a bullish story just like the fundamentals that the CEO described Thursday night. Traders could go long ARWR if prices go sideways for a day or two. Risk below $30 for now looking for gains to $44, and then $54 in the weeks and months ahead.

(Johnson & Johnson is a holding in Jim Cramer's Action Alerts PLUS member club. Want to be alerted before Jim Cramer buys or sells JNJ? Learn more now.)

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

Employees of TheStreet are prohibited from trading individual securities.

TAGS: Investing | Stocks | Technical Analysis | Trading | Biotechnology | Pharmaceuticals | Mad Money | Executive Interview

More from Investing

Marveling at the Market's Move? It's All About Momentum

James "Rev Shark" DePorre
Jan 19, 2021 4:41 PM EST

No news can explain the action -- whether the bears believe it or not.

Surface Oncology Is Set for Further Gains - How to Buy It

Bruce Kamich
Jan 19, 2021 3:25 PM EST

Here's our price objective.

My Preference With OneSpan Is Calls So I Can Define My Risk

Timothy Collins
Jan 19, 2021 2:36 PM EST

The last few post-earnings beat downs were greeted with optimism once traders got over the initial disappointment.

A Top Biotechnology Play for 2021

James "Rev Shark" DePorre
Jan 19, 2021 2:07 PM EST

Forte's sole clinic candidate is FB-401 for the treatment of atopic dermatitis, which is the scientific name for eczema.

Boot Barn Gets a Quant Upgrade: Do the Charts Fit?

Bruce Kamich
Jan 19, 2021 1:53 PM EST

Here's our latest analysis and trading strategy for the shares.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 11:09 AM EST GARY BERMAN

    Is Copper About to Turn to Rust?

    Below is a very long-term copper chart.  As you...
  • 08:02 AM EST GARY BERMAN

    Tuesday Morning Fibocall for for 1/19/2021

    SPX (Long-Term View) The 1/8/21 high @ 3826.69 i...
  • 09:01 AM EST JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    When it's time to sell, will you act or freeze?
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2021 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login